A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
- Marlow, R.
- Kuriyakose, S.
- Mesaros, N.
- Han, H.H.
- Tomlinson, Richard
- Faust, S. N.
- Snape, M. D.
- Pollard, A. J.
- Finn, A.
Publication date
April 2018
DOI Publisher
Elsevier BV Journal
issn:1873-2518Abstract
To evaluate the immunogenicity and safety of a reduced antigen diphtheria-tetanus-acellular pertussis-inactivated poliovirus (dTap-IPVB) vaccine (Boostrix-IPV, GSK) as a pre-school booster in 3-4 year old children as compared to dTap-IPVR (Repevax, Sanofi Pasteur), when co-administered with mumps-measles-rubella vaccine (MMRV)
Add to ORKG